Mega Lifesciences (MEGA) AGM 2025 summary

Opening remarks and agenda

• Meeting opened with introductions of CEO, CFO, Deputy CFO, and Company Secretary, outlining the agenda: financial performance review for 1H and 2Q 2024, CEO remarks, and Q&A session.

Financial performance review

• 1H 2024 revenue was THB 7.7 billion, flat year-on-year; branded business grew 2.5%.

• Distribution business revenue declined 8% (adjusted), mainly due to Myanmar consumer business; gross profit improved to 47.7% of revenue.

• SG&A expenses rose to 28.7% of revenue due to planned marketing; net profit was THB 991 million, flat year-on-year.

• CapEx of THB 99.7 million focused on maintenance and capacity expansion; THB 420 million planned for ESG and plant upgrades.

• 2Q 2024 revenue was THB 3.95 billion, flat year-on-year; branded business revenue up 6%.

• Gross profit in 2Q 2024 improved to 48.5% of revenue; adjusted net profit declined 13.2% due to forex loss in Nigeria.

Board and executive committee updates

• CEO highlighted stable branded and Pharma business growth, with distribution in Myanmar affected by external conditions.

• Pharma business now comprises about 45% of branded sales, with a strong pipeline of 170 new products under development.